[HTML][HTML] High glucose promotes Aβ production by inhibiting APP degradation

Y Yang, Y Wu, S Zhang, W Song - PloS one, 2013 - journals.plos.org
Y Yang, Y Wu, S Zhang, W Song
PloS one, 2013journals.plos.org
Abnormal deposition of neuriticplaques is the uniqueneuropathological hallmark of
Alzheimer's disease (AD). Amyloid β protein (Aβ), the major component of plaques, is
generated from sequential cleavage of amyloidβ precursor protein (APP) by β-secretase and
γ-secretase complex. Patients with diabetes mellitus (DM), characterized by chronic
hyperglycemia, have increased risk of AD development. However, the role of high blood
glucose in APP processing and Aβ generation remains elusive. In this study, we investigated …
Abnormal deposition of neuriticplaques is the uniqueneuropathological hallmark of Alzheimer’s disease (AD).Amyloid β protein (Aβ), the major component of plaques, is generated from sequential cleavage of amyloidβ precursor protein (APP) by β-secretase and γ-secretase complex. Patients with diabetes mellitus (DM), characterized by chronic hyperglycemia,have increased risk of AD development.However, the role of high blood glucose in APP processing and Aβ generation remains elusive. In this study, we investigated the effect of high glucose on APP metabolism and Aβ generation in cultured human cells. We found that high glucose treatment significantly increased APP protein level in both neuronal-like and non-neuronal cells, and promoted Aβ generation. Furthermore, we found that high glucose-induced increase of APP level was not due to enhancement of APP gene transcription but resulted from inhibition of APP protein degradation. Taken together, our data indicated that hyperglycemia could promote AD pathogenesis by inhibiting APP degradation and enhancing Aβ production. More importantly, the elevation of APP level and Aβ generation by high glucose was caused by reduction of APP turnover rate.Thus,our study provides a molecular mechanism of increased risk of developing AD in patients withDMand suggests thatglycemic control might be potentially beneficial for reducing the incidence of AD in diabetic patients and delaying the AD progression.
PLOS